Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ETC1
- Development stage
- Preclinical
- Lead developer
- AstraZeneca
- Modality
- Small Molecules
01
Overview
ETC1 (also known as ETC1 modulators) is a preclinical-stage small molecule program being developed by RejuvenRx and Iricor Therapeutics (IRICoR) for the treatment of leukemia (specifically acute myeloid leukemia) and solid tumors, including pancreatic cancer. The program focuses on the development of differentiated inhibitors of the mitochondrial electron transport chain complex I (ETC1), also known as NADH:ubiquinone oxidoreductase. By inhibiting complex I, these small molecules disrupt oxidative phosphorylation (OXPHOS) and cellular energy metabolism, selectively targeting OXPHOS-dependent cancer cells and leukemia stem cells while sparing normal cells. The program is currently in lead optimization.
- Other names
- ETC1 inhibitorsETC-1 inhibitorsETC 1 inhibitorsETC1 modulatorsETC-1 modulatorsETC 1 modulatorsElectron Transport Chain Complex I inhibitorsElectron Transport Chain Complex I modulators
02
Targets
ND1 (Mitochondrial electron transport chain complex I)
Beyond the preview
Go deeper on ETC1.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ETC1.